Last 12 months
- October 2023 (0)
- September 2023 (0)
- August 2023 (1)
- July 2023 (0)
- June 2023 (1)
- May 2023 (1)
- April 2023 (0)
- March 2023 (2)
- February 2023 (2)
- January 2023 (1)
- December 2022 (2)
- November 2022 (1)
- Show All
Tags
- Infection (1)
- Day of Immunology (17)
- Competition (9)
- ASI Membership (25)
- Visiting Speaker Program (4)
- Immunology (104)
- Closing Soon (4)
- Journals (18)
- Special Interest Groups (3)
- Immunology & Cell Biology (24)
- Women's Initiative (10)
- ASI Awards (59)
- Clinical & Translational Immunology (9)
- ASI (96)
- Event/Meeting (44)
- Vaccines (32)
- Show All
Latest News
Wednesday December 22, 2021
We welcome our new ASI Sustaining Member: AbbVie
AbbVie is proud to be named as a Sustaining Member of the Australian and New Zealand Society for Immunology (ASI). As a company that aims to make a remarkable impact on the lives of patients, advancing the science and education of immunology is a shared goal.
We are highly committed to developing and maintaining partnerships that ultimately benefit patients and fuel scientific progress. To create innovative solutions that go beyond treating the illness to have a positive impact on people’s lives, society – and science itself.
Science and innovation are the cornerstones of our business. Since 2013, AbbVie has invested over $50 billion in R&D along the research continuum of discovery, genomics, translational, precision medicine and clinical research. In Australia and New Zealand alone, AbbVie invests $31 million annually in clinical research funding. Over 2000 patients are participating in AbbVie funded trials, with 64 Phase III trials currently active of which 29 are in immunology.
At AbbVie we see a future of possibilities and we are investing accordingly. An additional 80 plus trials will commence in the next 2 years across Australia and New Zealand - 20 will be in immunology.
It’s the combination of great people and strong partnerships that enable us to build on the best ideas, wherever they originate. We look forward to our continued partnership with the ASI.
About AbbVie
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. Our heritage in Australia reaches back more than 80 years and we employ more than 450 people with our therapies currently benefiting more than 40,000 Australians. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments. Recently, we acquired Allergan which immediately diversified our business across several therapeutic areas: Immunology, Oncology, Virology, Neuroscience, Eye Care and Aesthetics.
For further information please visit www.abbvie.com.au. Follow @abbvie_AU on Twitter, Facebook, Instagram or our LinkedIn page.